Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Covington
Queensland Health
Mallinckrodt
McKesson
McKinsey
Healthtrust
US Army
Cipla

Generated: November 14, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021223

« Back to Dashboard

NDA 021223 describes ZOMETA, which is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the ZOMETA profile page.

The generic ingredient in ZOMETA is zoledronic acid. There are twenty-five drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the zoledronic acid profile page.
Summary for 021223
Tradename:ZOMETA
Applicant:Novartis
Ingredient:zoledronic acid
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 021223
Ingredient-typeDiphosphonates
Suppliers and Packaging for NDA: 021223
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZOMETA zoledronic acid INJECTABLE;IV (INFUSION) 021223 NDA Novartis Pharmaceuticals Corporation 0078-0387 0078-0387-25 1 VIAL in 1 CARTON (0078-0387-25) > 5 mL in 1 VIAL
ZOMETA zoledronic acid INJECTABLE;IV (INFUSION) 021223 NDA Novartis Pharmaceuticals Corporation 0078-0590 0078-0590-61 1 BOTTLE in 1 CARTON (0078-0590-61) > 100 mL in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;IV (INFUSION)StrengthEQ 4MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Aug 20, 2001TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;IV (INFUSION)StrengthEQ 4MG BASE/5ML
Approval Date:Mar 7, 2003TE:APRLD:Yes
Patent:➤ Sign UpPatent Expiration:Nov 29, 2025Product Flag?Substance Flag?Delist Request?Y

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;IV (INFUSION)StrengthEQ 4MG BASE/100ML
Approval Date:Jun 17, 2011TE:APRLD:Yes
Patent:➤ Sign UpPatent Expiration:Feb 5, 2028Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021223

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis ZOMETA zoledronic acid INJECTABLE;IV (INFUSION) 021223-001 Aug 20, 2001 ➤ Sign Up ➤ Sign Up
Novartis ZOMETA zoledronic acid INJECTABLE;IV (INFUSION) 021223-002 Mar 7, 2003 ➤ Sign Up ➤ Sign Up
Novartis ZOMETA zoledronic acid INJECTABLE;IV (INFUSION) 021223-002 Mar 7, 2003 ➤ Sign Up ➤ Sign Up
Novartis ZOMETA zoledronic acid INJECTABLE;IV (INFUSION) 021223-001 Aug 20, 2001 ➤ Sign Up ➤ Sign Up
Novartis ZOMETA zoledronic acid INJECTABLE;IV (INFUSION) 021223-003 Jun 17, 2011 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Julphar
Merck
Queensland Health
Farmers Insurance
Daiichi Sankyo
Medtronic
Teva
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.